Befejeződött3. fázis
Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers.
A legfontosabb adatok
- Ki végzi
- Anterogen Co., Ltd.
- Hol
- Dél-Korea5 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 3. fázis
- Résztvevők
- 104 fő vett részt
- Kezdés
- 2020. júl. 14.
- Befejezés
- 2024. dec. 5.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- ALLO-ASC-DFU
- Vehicle Sheet
- A regiszteradat frissítve
- 2025. szeptember 22.
Ki vehet részt
- Életkor
- 19 év – 75 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 35 feltétel megnézéseKevesebb
Ki vehet részt
- Subject is between 19 and 75 years of age
- Subject is diagnosed with Type I or Type II diabetics
- Diabetic foot ulcer has been more than 4 weeks but less than 52 weeks at the screening visit
- Ulcer located in the foot and ulcer size is between 1.5~15 cm2
- Ulcer graded 2 by Wagner grade
- Foot ulcer extended to ligament, tendon, joint capsule, fascia, muscle and periosteum
- Ulcer is free of necrotic debris
- Ulcer area blood circulation meets one of the following criteria; Blood vessels around the ulcer detected by Doppler Test; Range of Ankle Brachial Index (ABI) is > 0.7 to < 1.3; Transcutaneous Oxygen Pressure (TcPO2) > 30mmHg or Toe Blood Pressure (TBP) > 40mmHg; Skin Perfusion Pressure (SPP) > 30mmHg
- Subject is able to give written informed consent prior to study start and willing to comply with the study requirements
Ki nem vehet részt
- Have undergone wound treatments with growth factors, dermal substitutes, or other biological therapies within the last 30 days
- Is receiving oral or parenteral corticosteroids, any immunosuppressive, or cytotoxic agents with unstable dose within the last 30 days
- Ulcer is of non-diabetic pathophysiology
- There is gangrene in any part of the target foot ulcer
- The longest dimension of the target foot ulcer exceeds 15 cm at the enrollment visit
- Other wounds within 2cm of the target foot ulcer
- The ulcer has increased or decreased in size by ≥ 30% during two weeks after the screening visit
- Patient requiring intravenous (IV) antibiotics to treat foot wound infection at the screening and enrollment visit
- Current evidence of active charcot on the study foot, osteomyelitis, cellulitis, or evidence of other infection including fever or purulent drainage from wound site
- Patient with skin lesion confirmed by biopsy (when Investigator deems suspicious) and then judged by Investigator to be an etiology other than diabetic foot ulcer
- An active malignant tumor(malignant melanoma, squamous cell carcinoma, basal cell carcinoma) on the body or skin
- Is Human Immunodeficiency Virus (HIV) positive
- Have a known history of allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue
- Have a clinically relevant history of alcohol or drugs abuse at the screening visit
- Is considered by the Investigator to have a significant disease which might impact the study
- Have a history of malignancy within the last 5 years (except carcinoma in situ)
- Have a glycated hemoglobin A1c (HbA1c) level of > 14%
- Have severe renal failure with creatinine > 3.0mg/dL
- Have severe hepatic deficiencies; Total bilirubin ≥ 1.5×upper normal limit(UNL); AST, ALT ≥ 2.0×UNL; Serum albumin < 2.0mg/dL
- Have random blood sugar > 450mg/dL
- Pregnant or breast-feeding
- Is unwilling to use an acceptable method of birth control during the whole study
- Is not able to understand the objective of the study or to comply with the study requirements
- Is considered not suitable for the study by Investigator
- Is currently or were enrolled in another clinical study within 60 days of screening
- Cannot maintain off-loading process and device
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a phase III double-blind study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Diabetic Wagner grade 2 Foot Ulcer, compared to placebo therapy.
A vizsgálat 2 csoportja
- ALLO-ASC-DFUA vizsgált kezelés
Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
- Vehicle sheetPlacebo, összehasonlításként
Hydrogel sheet without allogenic mesenchymal stem cell
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Phase 3 Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers: A Randomized, Comparator-controlled, Double-blind, Parallel-group, Multi-center Study
- A regiszteradat frissítve
- 2025. szeptember 22.